25 Oct TPS Buy Report- CLLS- Cellectis
CLLS- Cellectis $32.50 Investors Website Shares Outstanding: 36 million Cash 200 Million Market Cap 1.15 Billion 80% Ownership of CLXT, currently valued at 650 Million, 80% of which is 520 Million value to CLLS on paper Gene Edited Off-the-shelf Immunotherapies: A Future-defining Shift in Simplicity, Availability, and Cost-effectiveness We first wrote about CLLS back in...